Joseph Monahan - Mar 1, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-fact
Stock symbol: ACRS
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/3/2022, 05:11 PM
Previous filing: Feb 11, 2022
Next filing: Mar 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+13.8K	+15.75%		101K	Mar 1, 2022	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+50K	+49.48%		151K	Mar 1, 2022	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+12.5K	+8.28%		164K	Mar 2, 2022	Direct	F1
holding	ACRS	Common Stock						193	Mar 1, 2022	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+153K		$0.00	153K	Mar 1, 2022	Common Stock	153K	$14.94	Direct	F2
transaction	ACRS	Restricted stock units	Award	$0	+43.7K		$0.00	43.7K	Mar 1, 2022	Common Stock	43.7K		Direct	F1, F3
transaction	ACRS	Restricted stock units	Options Exercise	$0	-13.8K	-50%	$0.00	13.8K	Mar 1, 2022	Common Stock	13.8K		Direct	F1, F4
transaction	ACRS	Restricted stock units	Options Exercise	$0	-50K	-25%	$0.00	150K	Mar 1, 2022	Common Stock	50K		Direct	F1, F5
transaction	ACRS	Restricted stock units	Options Exercise	$0	-12.5K	-33.33%	$0.00	25K	Mar 2, 2022	Common Stock	12.5K		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F3	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F4	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F5	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F6	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.